课题基金 / 基金详情

Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer

Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer
致命性转移性前列腺癌的驱动因素的定义和特征
批准号:
10579377
负责人:
Grinu Mathew
金额:
$36.88万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-01 至 2023-07-19

项目摘要

项目成果

Grinu Mathew的其他基金

相似基金

相关文献

中文摘要
翻译
前列腺癌(PC)是美国癌症相关死亡的第二大原因。我们的目标 拟议的研究是确定从惰性到致命的转变所必需的遗传因素 转移性前列腺癌我们已经从RapidCaP的肿瘤和转移中产生了原代细胞系, 致死PC的小鼠模型(PTEN和TP 53缺陷)。我们的初步数据突出了一个根本性的转变 与转移相关的细胞表型和生长信号。最重要的是 TAM激酶受体的丧失是这种转移相关的细胞重编程事件的关键。这些 离散的细胞状态与不同的信号行为相关,这使得或限制了 癌细胞的转移潜力。因此,我们现在的重点是描绘TAM激酶在PC中的作用, 转移和信号级联控制开关从原发性到远处转移性疾病, vivo.在这个建议中,我们将从机制上验证TAM受体在PC细胞谱系中的作用。 重编程和维持促转移EMT样表型(目的1和3)。接下来,我们将评估 PI 3 K/mTOR信号传导轴在TAM缺陷型PC中的作用(目的2)。为达致建议的目标,我们会 与受体信号传导和前列腺癌疾病生物学专家密切合作。我们的背景 在小鼠遗传学、细胞生物学和转化肿瘤学方面, 这项工作的提出和解开致命的转移性PC细胞的遗传依赖性。
英文摘要
Prostate cancer (PC) is the second leading cause of cancer-related deaths in the USA. The goal of our proposed research is to identify genetic factors that are essential for the switch from indolent to lethal metastatic prostate cancer. We have generated primary cell lines from tumor and metastasis of the RapidCaP mouse model for lethal PC (PTEN and TP53 deficient). Our preliminary data highlights a fundamental shift in cellular phenotype and growth signaling associated with the transition to metastasis. Most importantly, the loss of TAM kinase receptor is key for this metastasis associated cellular reprogramming event. These discrete cellular states are associated with divergent signaling behavior, which enables or restricts the metastatic potential of cancer cells. Therefore, our focus is now on delineating the role of TAM kinases in PC metastasis and the signaling cascade controlling the switch from primary to distant metastatic disease in vivo. In this proposal we will mechanistically validate the role of TAM receptors in PC cellular lineage reprogramming and maintenance of pro-metastatic EMT-like phenotype (Aims 1 and 3). Next, we will assess the role of PI3K/mTOR signaling axis in TAM-deficient PC (Aim 2). To execute the proposed aims, we will closely collaborate with experts in receptor signaling and prostate cancer disease biology. Our background in mouse genetics, cell biology and translational oncology is well aligned with the expertise required to carry out the proposed work and unravel the genetic dependencies of lethal metastatic PC cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer
Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer
海外基金